To view this email as a web page, click here.

 
Ophthalmology can ‘adopt’ technologies from other specialties
Many medical specialties share medications and technologies, from various classes of drugs to diagnostic testing and surgical instruments. Patients can benefits as physicians take advantage of new treatment options.
Read on
ADVERTISEMENT
 
Controlling adult glaucoma with cataract surgery, stent
As the second-leading cause of blindness worldwide, more than 3 million Americans suffer from glaucoma. A new procedure aims to relieve the mechanism and symptoms of the disease and help prevent blindness.
Find out more
 
New IOL design trends avoid negative dysphotopsias
Newer lab studies reveal increased posterior chamber depth does not cause ND and that any IOL, irrespective of material or edge design, implanted in the capsule bag can result in ND, which resolves when the very same inciting lens is moved from the bag to the ciliary sulcus.
Learn more
 
ADVERTISEMENT
Vision survey for cataract patients
Help your cataract patients make the best decision for their eyes by understanding their vision goals. Download this vision survey to share with your patients. Download the survey now.
 
RELATED ARTICLES
 
Examining comparable surgical methods for IOL dislocation
Intraoperative surgical methods key to AMD treatment
Treating dry eye with recombinant human nerve growth factor
Gene therapy for LHON: Deciphering phase III data
Budding technology could be an OCT analysis game-changer
Weigh risk, benefits of cataract surgery for your patients
Teleglaucoma lets patients be more engaged in care
 
ADVERTISEMENT
What’s new in dry eye?
This expert clinical resource from Ophthalmology Times discusses dry eye management following cataract and refractive surgeries, examines recent updates to treatment for Sjögren’s syndrome, and more. Get the latest on dry eye now.
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.